Anixa Advances Ovarian Cancer CAR-T Trial to Highest Dose Level with Promising Survival Data — Anixa Biosciences, Inc.

Event summary

Anixa Biosciences has treated the first patient in Cohort 5 of its Phase 1 trial for recurrent ovarian cancer, reaching a dose level of 1×10⁷ CAR-positive cells/kg.
No dose-limiting toxicities have been observed across any cohort up to and including the prior dose level of 3x106/kg CAR-T cells.
Five patients in the study have surpassed one year of survival following treatment, with one patient surviving beyond two years.
The trial is evaluating Lira-cel (liraltagene autoleucel), a novel FSHR-targeted CAR-T/CER-T therapy developed in collaboration with Moffitt Cancer Center.

The big picture

Anixa Biosciences' advancement to the highest dose level in its Phase 1 trial for recurrent ovarian cancer marks a significant milestone in the development of novel CAR-T therapies. The promising survival data, particularly in a highly pre-treated patient population, highlights the potential of Lira-cel to address a critical unmet need in oncology. This progress aligns with broader industry trends towards leveraging immune-based therapies for solid tumors, an area where traditional CAR-T therapies have historically faced challenges.

What we're watching

Therapeutic Efficacy: Whether the promising survival data from the Phase 1 trial will translate into broader clinical efficacy and regulatory approval.
Dose Optimization: The pace at which Anixa can optimize the dosing regimen to balance efficacy and safety in subsequent cohorts.
Market Differentiation: How Anixa's CER-T technology will differentiate itself from traditional CAR-T therapies in targeting solid tumors like ovarian cancer.